Insider Transactions in Q3 2025 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 02
2025
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
22,127
-4.85%
|
$44,254
$2.19 P/Share
|
|
Sep 02
2025
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
52,086
+10.24%
|
-
|
|
Sep 02
2025
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,250
-5.9%
|
$12,500
$2.19 P/Share
|
|
Sep 02
2025
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,306
+10.41%
|
-
|
|
Sep 02
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,448
-5.76%
|
$12,896
$2.19 P/Share
|
|
Sep 02
2025
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,697
+10.19%
|
-
|
|
Sep 02
2025
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,467
-1.15%
|
$4,934
$2.19 P/Share
|
|
Sep 02
2025
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,470
+2.48%
|
-
|